Journals / Tüberküloz ve Toraks / 2022 / Cilt: 70 - Sayı: 1

Subacute neurological sequelae in mild COVID-19 outpatients

Ayaktan hafif COVID-19 hastalarında subakut nörolojik sekeller

Pages
27–36
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: This study gives a description of neurological sequelae of mild COVID-19 at the subacute stage, in a relatively young group, and reveals that cognitive disturbances, as well as headache, are quite frequent.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Neurological aspect of COVID-19 is less understood compared to its respiratory and systemic effects.
📊
Key Findings & Data:We aimed to define subacute neurological sequelae in patients who recovered from mild COVID-19.
💡
Conclusion & Impact:Conclusion: This study gives a description of neurological sequelae of mild COVID-19 at the subacute stage, in a relatively young group, and reveals that cognitive disturbances, as well as headache, are quite frequent.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Neurological aspect of COVID-19 is less understood compared to its respiratory and systemic effects. We aimed to define subacute neurological sequelae in patients who recovered from mild COVID-19. Materials and Methods: This study enrolled long COVID patients who had mild infection, were non-hospitalized, and admitted to our hospital with neurological complaints occurring after COVID-19. The evaluation included detailed history of the symptoms, neurological examination, blood tests and necessary investigations relevant to their personal medical situation, and also a retrospective inquiry about their respiratory and neurological status during the acute phase of infection. Descriptive statistical measures, Chi-square and Student’s t-test were utilized. Results: We identified 50 patients (29F/21M) with a mean age of 36.9 ± 1.6 (mean ± SEM). The average time from COVID-19 to admission was 99 days(min-max= 15-247). Most frequent neurological complaints were headache (42%) and cognitive dysfunction (42%). Sleep disturbance (36%), prolonged anosmia (30%), prolonged ageusia (22%), fatigue (22%), and dizziness (8%) followed. Most patients with headache experienced headache also as an acute manifestation of COVID-19 (p= 0.02). Acute-stage sleep disorders were found to be more associated with subacute cognitive symptoms than other central symptoms (p= 0.008). The most common neurological symptom in the acute phase was headache (74%). Six patients, despite the absence of any acute-stage neurological symptoms, presented with emergence of subacute neurological sequela. There were only five patients with pulmonary involvement during the acute stage, who were not different from the rest of the cohort in terms of neurological sequelae. There was no increase of inflammatory markers in the blood tests at the subacute stage, or no association of the symptoms to biochemical parameters. Conclusion: This study gives a description of neurological sequelae of mild COVID-19 at the subacute stage, in a relatively young group, and reveals that cognitive disturbances, as well as headache, are quite frequent.

Özet

Giriş: COVID-19’un nörolojik yönü, solunumsal ve sistemik etkilerine kıyasla daha az bilinmektedir. Bu çalışmada, hafif COVID-19 geçirmiş hastalarda subakut nörolojik sekelleri tanımlamayı amaçladık. Materyal ve Metod: Çalışmaya hafif COVID-19 geçirmiş, hastaneye yatırılmadan izlenmiş ve sonrasında nörolojik şikayetlerle bize başvuran uzun COVID hastaları alındı. Değerlendirme sırasında semptomların ayrıntılı anamnezi alındı, nörolojik muayene yapıldı; kan testleri ve kendi tıbbi durumlarıyla ilgili gereken araştırmalar, ayrıca enfeksiyonun akut fazı sırasında respiratuvar ve nörolojik durumlarına yönelik geriye dönük bir sorgulama yapıldı. Tanımlayıcı istatistiksel parametreler, Ki-kare ve Student t-testi kullanıldı. Bulgular: Ortalama yaşı 36.9 ± 1.6 (ortalama ± SH) olan 50 hasta (29K/21E) tespit edildi. COVID-19’dan kabule kadar geçen ortalama süre 99 gündü (min-maks= 15-247). En sık görülen nörolojik şikayetler baş ağrısı (%42) ve bilişsel işlev bozukluğu (%42) idi. Bunu uyku bozukluğu (%36), uzamış anozmi (%30), uzamış aguzi (%22), yorgunluk (%22) ve baş dönmesi (%8) izlemekteydi. Baş ağrısı olan hastaların çoğu, aynı zamanda COVID-19’un akut bir belirtisi olarak da baş ağrısını yaşamışlardı (p= 0.02). Diğer merkezi semptomlara göre akut dönemdeki uyku bozukluklarının subakut kognitif semptomlarla daha fazla ilişkili olduğu bulundu (p= 0.008). Akut dönemde en sık görülen nörolojik semptom baş ağrısıydı (%74). Altı hasta herhangi bir akut dönem nörolojik semptomu olmamasına rağmen subakut nörolojik sorun gelişimi ile başvurmuştu. Akut dönemde pulmoner tutulumu olan sadece beş hasta vardı ve nörolojik sekeller açısından kohortun geri kalanından farklılık göstermiyordu. Subakut aşamada kan testlerinde enflamatuvar belirteçlerde artış yoktu ve semptomların biyokimyasal parametrelerle ilişkisi tespit edilmedi. Sonuç: Bu çalışma, nispeten genç bir grupta subakut aşamada hafif COVID-19’un nörolojik sekellerinin bir tanımını vermekte ve baş ağrısının yanı sıra bilişsel bozuklukların oldukça sık olduğunu ortaya koymaktadır.

🔖

Cite This Article

MUMCUOĞLU, T., EROĞLU, E., SAĞ, A. T., ÖZÜLKEN, K., POYRAZ, B. M., NUMANOĞLU, N., CANLAR, Ş. (2022). Subacute neurological sequelae in mild COVID-19 outpatients. Tüberküloz ve Toraks, Cilt: 70 - Sayı: 1, 27–36. https://ajindex.com/articles/618251

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020; 92(6): 552-5.
  2. Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol 2021; 23: 1-13.
  3. Nordvig AS, Rimmer KT, Willey JZ, Thakur KT, Boehme AK, Vargas WS, et al. Potential neurological manifestations of COVID-19. Neurol Clin Prac 2021; 11(2): e135-e146.
  4. Wang L, Shen Y, Li M, Chuang H, Ye Y, Zhao H, et al. Clinical manifestations and evidence of neurological involvement in 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. J Neurol 2020; 267(10): 2777-89. https://doi.org/10.1007/s00415-020- 09974-2 5. Newcombe VFJ, Dangayach NS, Sonneville R. Neurological complications of COVID-19. Intensive Care Med 2021; 47: 1021-3. https://doi.org/10.1007/s00134-021-06439- 6 Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 2020; 77(8): 1018- 27.
  5. Osuchowski MF, Winkler MS, Skirecki T, Cajander S, Shankar Hari M, Lachmann G, et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 2021; 9(6): 622- 42.
  6. Sridhar S, Nicholls J. Pathophysiology of infection with SARS-CoV-2-What is known and what remains a mystery. Respirology 2021; 26(7): 652-65. https://doi. org/10.1111/resp.14091 9. Garcia Monco JC, Cabrera Muras A, Erburu Iriarte M, Rodrigo Armenteros P, Collía Fernández A, Arranz Martínez J, et al. Neurological manifestations in a prospective unselected series of hospitalized COVID-19 patients. Neurol Clin Prac 2021; 11(2): e64-e72. https://doi. org/10.1212/CPJ.0000000000000913 10. Anand P, Zhou L, Bhadelia N, Hamer DH, Greer DM, Cervantes-Arslanian AM. Neurologic findings among inpatients with COVID-19 at a safety-net US hospital. Neurol Clin Prac 2021; 11(2): e83-e91. https://doi.org/10.1212/ CPJ.0000000000001031 11. Fleischer M, Köhrmann M, Dolff S, Szepanowski F, Schmidt K, Herbstreit F, et al. Observational cohort study of